The Ariad vets developing next-gen TKIs are heading back to Nasdaq — and OrbiMed stands to reap the most
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
By June 2018, the dust on Takeda’s $5.2 billion buyout of Ariad Oncology had long settled. The biotech’s oncology and hematology portfolio was in the hands of the pharma’s commercial team; execs moved onto new gigs; and on the pipeline front, Takeda was steering a slate of candidates through trials.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,700+ biopharma pros reading Endpoints daily — and it's free.